Investigators reported a randomized, sham-controlled clinical trial comparing acupuncture (real acupuncture, RA) with sham acupuncture (SA) in adults diagnosed with mild to moderate depressive disorder. Treatment was standardized and delivered over an 8-week period. The study team assessed clinical status at baseline, during treatment (with effects noted by Week 4), and up to 12 weeks after the end of treatment. The abstract states that a subset of participants underwent neuroimaging with fNIRS during both resting-state and task-based conditions to evaluate prefrontal cortical responses. The abstract did not report sample size, demographic details, exact acupuncture points, session frequency, or the sham procedure specifics; those methodological elements were not provided in the source abstract.
Data indicated that patients in the RA group showed meaningful reductions in symptom scores relative to baseline on the Self-Rating Depression Scale (SDS) and the Self-Rating Anxiety Scale (SAS). The study team observed that symptom improvement emerged by Week 4 of treatment and persisted through the 12-week post-treatment follow-up. SF-36 health-survey results reflected improvements in emotional-domain measures for the RA cohort. Authors noted that these clinical gains were greater and more stable in the RA group than in the SA group. The abstract cites a traditional Chinese medicine syndrome score as an additional clinical measure; no values or statistical details were included in the abstract itself. The report did not include exact effect sizes, p-values, or responder/remitter rates in the abstract, so those metrics cannot be summarized here without access to the full text.
A predefined subset underwent fNIRS imaging to probe cortical changes associated with treatment. The authors reported enhanced activation in both dorsolateral and medial prefrontal regions following real acupuncture. In parallel, they observed strengthened prefrontal functional connectivity post-treatment in the RA group. Neural alterations in the SA group were described as limited in comparison. The abstract indicates that both resting-state and task-based fNIRS paradigms were used, but it does not specify the number of participants imaged, the tasks administered, recording parameters, channels or regions of interest, preprocessing steps, or connectivity metrics employed. Those technical details were not provided in the abstract and therefore are not reported here.
The study team proposed a mechanistic link between the clinical improvement in depressive and anxiety symptoms and modulation of prefrontal cortical activation and connectivity detected by fNIRS. Authors suggested that increased dorsolateral and medial prefrontal engagement and strengthened prefrontal network interactions might underlie the antidepressant-like effects observed after real acupuncture. This interpretation is presented in the abstract as an association between clinical change and cortical measures; the abstract does not describe causal testing, mediation analyses, or longitudinal neurobehavioral modeling, so causality cannot be inferred from the summary alone.
The authors declared no known competing financial interests or personal relationships that could have appeared to influence the work reported. The abstract did not list adverse events or safety outcomes, nor did it detail tolerability or withdrawal rates. Important methodological information absent from the abstract includes participant numbers, baseline demographic or clinical characteristics, blinding verification, precise acupuncture protocols (points, needle depth, stimulation parameters), sham-control design specifics, fNIRS acquisition and analysis parameters, and statistical values for reported outcomes. These omissions limit the ability to evaluate internal validity and reproducibility from the abstract alone.
The abstract documents positive clinical and cortical findings after 8 weeks of acupuncture with persistence to 12 weeks, but it leaves key questions unanswered: the sample size and statistical strength of reported differences are not reported in the abstract; demographic composition and illness duration are not provided; the exact sham method and blinding integrity are unspecified; and fNIRS technical and analytic details are absent. The study team did not report adverse-event rates in the abstract. Access to the full text is required to appraise effect magnitude, methodological rigor, and generalizability. The paper is published in Neuropharmacology with a DOI listed, and the authors declared no competing interests, but additional details necessary for guideline consideration and clinical implementation are not available in the source abstract.